MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4103/jpbs.jpbs_498_20

Медицинская библиотека · Journal of pharmacy & bioallied sciences · 2021

A Narrative Review of Antiviral Drugs Used for COVID-19 Pharmacotherapy.

Kumar Subodh, Saurabh Manoj K, Maharshi Vikas, Saikia Dibyajyoti

СтатьяОбзорПеревод в очереди

Аннотация

PURPOSE: A number of research articles has been published evaluating safety and efficacy of drugs against COVID-19. This study was undertaken to collate and review the information regarding common proposed anti- viral drugs for easy reference.

METHODS

The literature was search was done using terms like severe acute respiratory syndrome or SARS-CoV-2 or 2019-nCoV or SARS-CoV or COVID-19 in combination with drugs or treatment or pharmaco-therapy using PubMed and google scholar to identify relevant articles.

RESULTS

Despite showing good early results, hydroxychloroquine and lopinavir-ritonavir has not shown clinical benefit in randomized controlled trials. However lopinavir in combination with other drugs specially interferon is being investigated. Remdesivir has shown positive effect in terms of clinical improvement and continued to being investigated alone or in combination with other drugs. Favipiravir has shown mixed results and more data from adequately powered study is needed to prove its efficacy.

CONCLUSIONS

Many drugs which showed positive effect in initial studies could not replicate the same benefit in large randomized controlled trials. There is need to evaluate efficacy and safety of drugs based on high quality evidence before allowing it to be used in general population.

Для цитирования: Kumar Subodh, Saurabh Manoj K, Maharshi Vikas, Saikia Dibyajyoti. A Narrative Review of Antiviral Drugs Used for COVID-19 Pharmacotherapy.. Journal of pharmacy & bioallied sciences. 2021. DOI: 10.4103/jpbs.jpbs_498_20.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.